A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1 in Metastatic Castration Resistant Prostate Cancer (CRPC).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs TL 118 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Dec 2013 Planned End Date changed from 1 Aug 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 27 Dec 2010 Planned end date changed from 1 Aug 2010 to 1 Aug 2012 as reported by ClinicalTrials.gov.